Nurturing innovation

Adipo Therapeutics is advancing the treatment of obesity by increasing energy expenditure through the unique benefits of brown fat.

AKICept is advancing a clinical-stage endovascular treatment to reverse ischemia reperfusion-caused acute kidney injury before permanent kidney damage, dialysis or mortality occurs.

Amplicore develops injectable therapeutics for degenerative musculoskeletal disorders that address the underlying causes of joint discomfort by taking a regenerative approach to joint osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tear.

Early is Good is developing the Multi-omic Integration Platform to bring together DNA, RNA, protein, and metabolite detection in one test, enabling earlier and more precise cancer diagnosis.

Entomol is the exclusive producer of the EPA-approved insect repellent hydrogenated catmint (Nepeta cataria) oil, the only insect repellent ingredient on the market combining the efficacy of the best synthetics with a safety profile permitting unlimited application to adults and children.

Helix BioStructures LLC is an Indianapolis-based gene-to-structure CRO that partners with drug discovery teams to turn challenging protein targets into clear, decision-ready insights by applying deep structural biology expertise spanning custom protein production, biophysical characterization (e.g., mass photometry, SPR, ITC), Xray crystallography, and cryo-EM.

Kovina Therapeutics is a preclinical biotechnology company developing targeted antiviral therapeutics designed to eliminate HPV-driven cancers and prevent the progression of premalignant infections caused by Human Papillomavirus (HPV).

Monument Biosciences is dedicated to bringing forward the next generation of disease modifying drugs for Alzheimer’s Disease and Related Dementias (ADRD). Its discovery programs are anchored in human patient genetics, recent discoveries around tau homeostasis and tau seeding, and the role of microglia in neuroinflammation.

NĒRx Biosciences is a preclinical stage biotechnology company focused on the discovery and development of novel small molecule inhibitors targeting the DNA Damage Response (DDR) pathway. The company’s primary goal is to develop a new generation of anticancer therapeutics that are directed against novel protein targets for the treatment of lung and ovarian cancer.

P2K Dynamics is developing next generation drugs that target novel mechanisms for the treatment of multiple myeloma and other cancers that have become resistant to available treatment or have limited therapeutic options.

Syndeio Biosciences is a synapse-focused biotech pioneering a new class of therapies for neuropsychiatric and cognitive disorders. Its key innovation is harnessing event-driven pharmacology — a mechanism where a single drug dose triggers lasting biological changes that strengthen the connection between neurons. This approach opens new possibilities for creating rapid-acting, safe, and effective therapies.

Teichos Laboratories, LLC is an Indiana-based, chemistry-focused immunotherapy B2B company that manufactures and supplies agents from our biomolecular platform to commercial partners for use in their existing and development-phase technologies. It uses natural products chemistry, employing chemoenzymatic synthesis to access and modify a totally synthetic peptidoglycan (sPGN) core structure to produce new chemical entities for diverse drug applications.

Vasculonics is a preclinical stage biotechnology company focused on developing a new class of disease modifying medicine to reduce disease progression and mortality in pulmonary artery hypertension (PAH) and chronic kidney disease (CKD).

Xylogenics Inc. is a synthetic biology company that creates valuable, non-consumed yeast to enable fermentation-based production of natural products. It is redefining fermentation, starting with a flagship product for the fuel ethanol market.